NEWS
- Monodisperse (Discrete) PEGylation vs. Polydisperse PEGylation: Future Trends
- ROR1 ADCs in Clinical Trials: MK-2140, NBE-002 & CS5001
- FDA Approves Datroway (Datopotamab Deruxtecan) in HR+/HER2– Breast Cancer
- Claudin6 (CLDN6): A Emerging Target For Solid Tumor
- New Oncology Trends: ADCs, Bispecific Antibodies & CAR-T Cell
- Development of Current Four Generation ADCs And Next Generation ADCs
- Aptamer-Drug Conjugate (ApDC): Current Research Progress
- ADC Drugs Targeting Claudin18.2
- Application of mRNA-Lipid Nanoparticles (LNPs) In Cancer
- Emerging Antibody–siRNA Conjugates (ARC)
